Scopolamine is an anticholinergic alkaloid drug which works by blocking the neurotransmitter acetylcholine in the brain. It is widely used to treat motion sickness, gastrointestinal disorders, and other conditions. Scopolamine-based transdermal patches and gels are commonly used products to prevent motion sickness caused while travelling via sea, road, air etc. as they provide consistent drug delivery over an extended period of time with minimum side effects. The global rise in recreational and business travel has significantly increased the incidences of motion sickness, thereby driving the demand for scopolamine-based pharmaceutical products.
Market Opportunity
The growing travel and tourism industry presents a major market opportunity for scopolamine products. According to the United Nations World Tourism Organization (UNWTO), international tourist arrivals grew by 4% in 2019 to reach 1.5 billion globally. Countries in Asia Pacific such as China, India and Southeast Asian nations are witnessing strong growth in domestic and international travel. As motion sickness commonly occurs while travelling via road, air or sea, the rising tourism business is expected to significantly drive the demand for scopolamine-based formulations for preventing nausea, vomiting and dizziness associated with it. Key players can leverage this opportunity by introducing novel drug delivery systems such as transdermal patches and gels targeting tourists and business travelers in Asia Pacific and other fast growing travel markets.
Porter's Analysis
Threat of new entrants: The scopolamine market is moderately competitive due to stringent regulations. New entrants need significant R&D investments and clinical trials to penetrate this market.
Bargaining power of buyers: The bargaining power of buyers is low due to lack of substitution and specialized nature of products in this market.
Bargaining power of suppliers: Major suppliers like Integra LifeSciences hold significant bargaining power due to their established product offerings and manufacturing capabilities.
Threat of new substitutes: Threat of substitutes is low as scopolamine offers unique benefits in treating motion sickness with minimal side effects.
Competitive rivalry: The market is dominated by few large players who compete on the basis of portfolio expansion, pricing, and innovation.
SWOT Analysis
Strengths: Growing incidence of motion sickness and post-surgical care is driving the market. Scopolamine offers effective relief without drowsiness.
Weaknesses: Availability of alternative medicines and generics poses pricing pressure. Side effects associated with overdose like blurred vision and dry mouth.
Opportunities: Introduction of advanced drug delivery technologies and combination therapies presents new avenues. Emerging markets like Asia Pacific offer high growth potential.
Threats: Stringent regulations delay product approvals. Exposure to price erosion due to patent expiries of major drugs.
Key Takeaways
Global Scopolamine Market Size is expected to witness high growth over the forecast period supported by rising incidence of motion sickness worldwide. The global scopolamine market is estimated to be valued at US$ 3,676.85 Bn in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030.
The North America region currently dominates the market owing to well-established healthcare system and growing adoption of advanced anti-emetic therapies in the US and Canada. Asia Pacific is expected to be the fastest growing regional market for scopolamine driven by large patient population, low-cost manufacturing, and improving access to healthcare in India and China. Other emerging nations like South Korea, Japan, and Southeast Asian countries will further aid the growth of this regional market.
Key players: Key players operating in the scopolamine market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, Becton, Dickinson and Company, Smith & Nephew Plc., Organogenesis Holdings Inc., Tissue Regenix, Zimmer Biomet Holdings, Inc., Stryker Corporation, Baxter International Inc., and 3M.
Explore More Related Article On This Topic: https://www.newsanalyticspro.com/scopolamine-market-poised-to-propelled-by-increasing-prevalence/
Explore More Related Article: https://thewion.com/read-blog/140661
Comments
0 comment